SCM
SRPT icon

Shelton Capital Management’s Sarepta Therapeutics SRPT Stock Holding History

Shelton Capital Management’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-3,505
Closed -$224K – 743
2025
Q1 		$224K Sell
3,505
-94
-3% -$9.89K 0.01% 618
2024
Q4 		$438K Sell
3,599
-138
-4% -$16.9K 0.01% 384
2024
Q3 		$467K Sell
3,737
-81
-2% -$11.2K 0.01% 363
2024
Q2 		$603K Buy
+3,818
New +$490K 0.02% 310

Other funds holding SRPT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Shelton Capital Management's SRPT Position: Q2 2025 in Review

Shelton Capital Management sold out of Sarepta Therapeutics (SRPT) in Q2 2025, closing a stake of 3,505 shares — an estimated $224K sold.

Shelton Capital Management first reported a position in SRPT in Q2 2024 and held it in 4 quarters. The position peaked at $603K in Q2 2024. 362 funds tracked by Wall St. Rank hold SRPT as of Q2 2025.

  • Shelton Capital Management reported no remaining Sarepta Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Shelton Capital Management sold 3,505 Sarepta Therapeutics shares in Q2 2025, an estimated $224K.
  • Shelton Capital Management first reported a position in Sarepta Therapeutics in Q2 2024 and held it in 4 quarters.
  • Shelton Capital Management's Sarepta Therapeutics position peaked at $603K in Q2 2024.
  • 362 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2025.

Based on Shelton Capital Management's 13F filing for Q2 2025, filed 13 Aug 2025.